GIST sets out to develop a next generation diagnostic biosensor

-      Establishment of Inji Bio co. in joint with Infofia and KRIBB

-      Development of a diagnostic biosensor for cardiovascular disorders and myocardial infarction

-       200 billion won in annual sales and 200 jobs to be created

 

   On October 26^th, Gwangju Institute of Science and Technology (GIST· President, Kim Young-Joon) announced Inji Bio co. ltd was established as a joint research corporation among industry, academia and research institution, which is charged with the development of next generation diagnostic biosensors based on the source biotechnologies owned by Advanced Photonics Research Institute (APRI, Director Lee In-Won) and a team led by professor Kim Min-Gon of the School of Physics and Chemistry.

 

   The foundation of Inji Bio was organized by GIST and participated by Infofia and Korea Research Institute of Bioscience and Biotechnology (KRIBB). It plans to develop a trial sensor product to diagnose toxic materials such as pesticides by 2015 and then push ahead with the development of a high speed & sensitivity biosensor to diagnose cardiovascular disorders and myocardial infarction. This biosensor is expected to diagnose several types of diseases at once with only small blood samples in just ten minutes and be easy to use for ordinary people.